1338 Federal Register / Vol. 72, No. 7 / Thursday, January 11, 2007 / Notices 

Dental & Craniofacial Research, National 

Institutes of Health, Bethesda, MD 20892, 

(301) 594–4827, kims@email.nidr.nih.gov. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel 07–40, Review R21. 

Date: March 6, 2007. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892 (Telephone Conference Call). 

Contact Person: Lynn M. King, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, 45 Center Dr., Rm 4AN–32F, 

National Institute of Dental & Craniofacial 

Research, National Institutes of Health, 

Bethesda, MD 20892–6402, 301–594–5006, 

lynn.king@nih.gov. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel 07–29, Review R21s. 

Date: March 9, 2007. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892 (Telephone Conference Call). 

Contact Person: Lynn M. King, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, 45 Center Dr., Rm 4AN–32F, 

National Institute of Dental & Craniofacial 

Research, National Institutes of Health, 

Bethesda, MD 20892–6402, 301–594–5006, 

lynn.king@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: January 3, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–73 Filed 1–10–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse, 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Centers 

Review Committee. 

Date: February 19, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Rita Liu, PhD, Associate 

Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 212, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, 

301.435.1388, rliu@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel Program 

Projects. 

Date: February 20, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Rita Liu, PhD, Associate 

Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 212, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, 

301.435.1388, rliu@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, 

Medication Development Research 

Subcommittee. 

Date: March 5, 2007. 

Time: 8:30 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott at Metro Center, 775 12th 

Street, NW., Washington, DC 20005. 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Blvd, Bethesda, MD 

20892–8401, 301–402–6626, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Health 

Services Research Subcommittee. 

Date: March 6–7, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Meenaxi Hiremath, PhD, 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, National Institutes of Health, 

DHHS, 6101 Executive Blvd., Suite 220, MSC 

8401, Bethesda, MD 20892, 301–402–7964, 

mh392g@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Treatment 

Research Subcommittee. 

Date: March 6–7, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Kesinee Nimit, MD, Health 

Scientist Administrator, Office of Extramural 

Affairs, National Institute on Drug Abuse, 

NIH, DHHS, Room 220, MSC 8401, 6101 

Executive Boulevard, Bethesda, Md 20892–

8401, (301) 435–1432. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Training 

and Career Development Subcommittee. 

Date: March 13–15, 2007. 

Time: 9 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Eliane Lazar-Wesley, PhD, 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, 6101 Executive 

Boulevard, Room 220, MS 8401, Bethesda, 

MD 20892–8401, 301–451–4530, 

el6r@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: January 3, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–76 Filed 1–10–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

Technical Support for Constituency Outreach 

and Research Dissemination. 

Date: February 1, 2007. 

Time: 9:30 a.m. to 11:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 


cprice-sewell on PROD1PC66 with NOTICES